Emerald Labs Ltd 15776578 false 2024-06-13 2025-11-30 2025-11-30 The principal activity of the company is Health Support Digita Accounts Production Advanced 6.30.9574.0 true 15776578 2024-06-13 2025-11-30 15776578 2025-11-30 15776578 core:CurrentFinancialInstruments 2025-11-30 15776578 core:CurrentFinancialInstruments core:WithinOneYear 2025-11-30 15776578 core:OfficeEquipment 2025-11-30 15776578 bus:SmallEntities 2024-06-13 2025-11-30 15776578 bus:AuditExemptWithAccountantsReport 2024-06-13 2025-11-30 15776578 bus:FilletedAccounts 2024-06-13 2025-11-30 15776578 bus:SmallCompaniesRegimeForAccounts 2024-06-13 2025-11-30 15776578 bus:RegisteredOffice 2024-06-13 2025-11-30 15776578 bus:Director1 2024-06-13 2025-11-30 15776578 bus:Director2 2024-06-13 2025-11-30 15776578 bus:Director3 2024-06-13 2025-11-30 15776578 bus:Director4 2024-06-13 2025-11-30 15776578 bus:PrivateLimitedCompanyLtd 2024-06-13 2025-11-30 15776578 bus:Agent1 2024-06-13 2025-11-30 15776578 core:OfficeEquipment 2024-06-13 2025-11-30 15776578 countries:EnglandWales 2024-06-13 2025-11-30 iso4217:GBP xbrli:pure

Registration number: 15776578

Emerald Labs Ltd

Annual Report and Unaudited Financial Statements

for the Period from 13 June 2024 to 30 November 2025

 

Emerald Labs Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Emerald Labs Ltd

Company Information

Directors

Mr A Badalyan

Mr A Shchipanov

Mr D D McNally

Mr B Torrero

Registered office

71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

Accountants

Rotherham Taylor Limited 21 Navigation Business Village
Navigation Way
Ashton-on-Ribble
Preston
PR2 2YP

 

Emerald Labs Ltd

(Registration number: 15776578)
Balance Sheet as at 30 November 2025

Note

2025
£

Fixed assets

 

Tangible assets

4

730

Current assets

 

Debtors

5

897

Cash at bank and in hand

 

1,034,060

 

1,034,957

Creditors: Amounts falling due within one year

6

(90,164)

Net current assets

 

944,793

Total assets less current liabilities

 

945,523

Provisions for liabilities

(182)

Net assets

 

945,341

Capital and reserves

 

Called up share capital

13

Share premium reserve

1,544,776

Retained earnings

(599,448)

Shareholders' funds

 

945,341

For the financial period ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 22 April 2026 and signed on its behalf by:
 

.........................................
Mr A Badalyan
Director

   
     
 

Emerald Labs Ltd

Notes to the Unaudited Financial Statements for the Period from 13 June 2024 to 30 November 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Emerald Labs Ltd

Notes to the Unaudited Financial Statements for the Period from 13 June 2024 to 30 November 2025

Research and development

In the research phase of a project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research is recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured.

Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

25% on cost

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Emerald Labs Ltd

Notes to the Unaudited Financial Statements for the Period from 13 June 2024 to 30 November 2025

Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss. Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 2.

 

Emerald Labs Ltd

Notes to the Unaudited Financial Statements for the Period from 13 June 2024 to 30 November 2025

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

Additions

973

973

At 30 November 2025

973

973

Depreciation

Charge for the period

243

243

At 30 November 2025

243

243

Carrying amount

At 30 November 2025

730

730

5

Debtors

Current

2025
£

Trade debtors

897

 

897


 

 

Emerald Labs Ltd

Notes to the Unaudited Financial Statements for the Period from 13 June 2024 to 30 November 2025

6

Creditors

Creditors: amounts falling due within one year

Note

2025
£

Due within one year

 

Loans and borrowings

7

527

Trade creditors

 

11,407

Taxation and social security

 

9,348

Accruals and deferred income

 

68,882

 

90,164

7

Loans and borrowings

Current loans and borrowings

2025
£

Director's loan account

527

The director's loan account is non-interest bearing and has no formal repayment terms.